Micromedex, Health Care Series. Thomson Health Care, Greenwood Village, Colorado, USA, 2007.
Peyriere H, Cociglio M, Margueritte G, Vallat C, Blayac JP, Hillaire-Buys D. Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother. 2004;38:422–7.
Tortajada-Ituren J, Ordovas-Baines J, Llopis-Salvia P, Jimenez-Torres N. High-dose methotrexate-doxycycline interaction. Ann Pharmacother. 1999;33:804–8.
Lam M, Ignoffo R. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract. 2003;9:45. doi:10.1191/1078155203jp107oa.
www.cancer.gov/clinicaltrials/EORTC-58951.
EsPhALL: European Intergroup Study on post-induction treatment of PhALL (Phase II/III study).
Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34:1024–7.
Reid T, Yuen A, Catolico M, et al. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol. 1993;33:82–4.
Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate clearance. Cancer Chemoter Pharmacol. 1999;44:88–9.
http://mqa.dhs.state.tx.us/QMWeb/MedSim/Naranjo.htm. Accessed on 4 Feb 2008.